This report provides an analysis of the external quality assessment (EQA) for the antimicrobial susceptibility testing (AST) performance of laboratories participating in the European Antimicrobial Resistance Surveillance Network (EARS-Net) in 2019. A total of 952 laboratories (1–95 per country) from 30 EU/EEA countries participated in the EQA exercise.
For 2018, EU/EEA countries reported 13 travel-related cases of yellow fever. The cases were reported by France (7), Germany (2), Czechia (1), the Netherlands (1), Romania (1) and the United Kingdom(1). The case reported by the Netherlands acquired the infection in Senegal or Gambia. All other cases acquired the infection in Brazil. This was the highest number of yellow fever cases ever reported in the EU/EEA in one year. In the previous four years, only one case was reported: the Netherlands reported an imported case with a travel history to Suriname.
Depending on the level of evidence provided and the methodology used, this advice is typically conveyed through a Guidance, a Systematic review or an Expert opinion.
HIV combination prevention is an approach that brings together single prevention initiatives into a comprehensive programme. This approach considers that the offer of multiple evidence-based interventions in a comprehensive programme will have a greater impact on HIV transmission than investing in a single strategy. In this report we
present and test the feasibility of a novel approach to monitoring the implementation of combination HIV prevention at national level.
European Testing Week is a European campaign that encourages partner organisations, in community, health care and policy institutions, throughout Europe to unite for one week twice a year to increase testing efforts and promote awareness on the benefits of earlier hepatitis and HIV testing.
This document summarises evidence from studies included in the licensing file of HPV vaccines together with postlicensure, peer-reviewed data and analysis where available. This guidance does not address the safety of HPV vaccines observed during the pre- and post-licensing period.